Handelsbanken Fonder AB Has $4.38 Million Stake in Charles River Laboratories International, Inc. $CRL

Handelsbanken Fonder AB raised its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 36.9% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 19,306 shares of the medical research company’s stock after acquiring an additional 5,200 shares during the period. Handelsbanken Fonder AB’s holdings in Charles River Laboratories International were worth $4,378,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Jones Financial Companies Lllp lifted its holdings in shares of Charles River Laboratories International by 167.6% during the 1st quarter. Jones Financial Companies Lllp now owns 1,715 shares of the medical research company’s stock worth $253,000 after acquiring an additional 1,074 shares during the period. Empowered Funds LLC bought a new stake in shares of Charles River Laboratories International during the first quarter worth $418,000. American Century Companies Inc. grew its position in shares of Charles River Laboratories International by 41.9% during the 2nd quarter. American Century Companies Inc. now owns 5,469 shares of the medical research company’s stock worth $830,000 after buying an additional 1,616 shares during the period. Brown Advisory Inc. boosted its position in shares of Charles River Laboratories International by 5.1% in the 2nd quarter. Brown Advisory Inc. now owns 2,333 shares of the medical research company’s stock worth $354,000 after purchasing an additional 114 shares during the last quarter. Finally, California Public Employees Retirement System increased its stake in shares of Charles River Laboratories International by 3.9% in the 2nd quarter. California Public Employees Retirement System now owns 84,605 shares of the medical research company’s stock valued at $12,837,000 after acquiring an additional 3,198 shares during the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Price Performance

Shares of NYSE CRL opened at $279.70 on Friday. Charles River Laboratories International, Inc. has a 1-year low of $144.26 and a 1-year high of $288.02. The firm has a market cap of $13.35 billion, a price-to-earnings ratio of -57.67, a price-to-earnings-growth ratio of 2.92 and a beta of 1.38. The company has a current ratio of 1.35, a quick ratio of 1.04 and a debt-to-equity ratio of 0.92. The stock has a fifty day simple moving average of $224.87 and a two-hundred day simple moving average of $191.33.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 EPS for the quarter, beating the consensus estimate of $2.77 by $0.25. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The company had revenue of $1 billion during the quarter, compared to analysts’ expectations of $980.53 million. During the same quarter in the previous year, the company earned $3.12 earnings per share. Charles River Laboratories International’s revenue for the quarter was down 2.7% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Analysts anticipate that Charles River Laboratories International, Inc. will post 11.35 earnings per share for the current year.

Insider Buying and Selling at Charles River Laboratories International

In related news, CAO Michael Gunnar Knell sold 6,645 shares of the firm’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $260.38, for a total value of $1,730,225.10. Following the completion of the sale, the chief accounting officer owned 11,852 shares of the company’s stock, valued at $3,086,023.76. This trade represents a 35.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director James C. Foster sold 75,000 shares of the firm’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $225.00, for a total value of $16,875,000.00. Following the transaction, the director directly owned 31,596 shares of the company’s stock, valued at $7,109,100. This represents a 70.36% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 129,817 shares of company stock valued at $31,774,935. 1.30% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

CRL has been the topic of a number of recent research reports. Royal Bank Of Canada lifted their target price on Charles River Laboratories International from $215.00 to $282.00 and gave the company an “outperform” rating in a research report on Thursday, August 6th. Piper Sandler set a $300.00 price objective on shares of Charles River Laboratories International in a research report on Monday. Weiss Ratings upgraded shares of Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 1st. BNP Paribas Exane set a $250.00 price objective on Charles River Laboratories International in a research report on Wednesday, July 1st. Finally, TD Cowen boosted their target price on shares of Charles River Laboratories International from $235.00 to $300.00 and gave the company a “buy” rating in a report on Monday. Twelve investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $255.65.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.